APA (7th ed.) Citation

Hygino J, Sales MC, Sacramento PM, Kasahara TM, da Silva JCC, Bilhão R, . . . Bento CA. (2024). Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure. Dove Medical Press.

Chicago Style (17th ed.) Citation

Hygino J, Sales MC, Sacramento PM, Kasahara TM, da Silva JCC, Bilhão R, Andrade RM, Vasconcelos CCF, and Bento CA. Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands Is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure. Dove Medical Press, 2024.

MLA (9th ed.) Citation

Hygino J, et al. Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands Is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure. Dove Medical Press, 2024.